ANTX · AN2 Therapeutics, Inc. · Metrics
$3.60
+0.04 (+1.12%)
At close · Oct 21
Return incl. dividend (before tax)
Market Cap
$142.08M
Shares
37.74M
Volume · Oct 21
177.37K
Avg daily vol (3M)
249.97K
ANTX metrics
64 of 122 screener metrics currently available.
Market overview
2 metricsShare price
$3.60
Market cap
$142.08M
Price action
20 metricsPrice change (1W)
-1.1%
Price change (30D)
-28.2%
Price change (3M)
-28.8%
Price change (6M)
-6.3%
Price change (YTD)
+212.3%
Price change (1Y)
+191.8%
Trailing year
Price change (5Y)
—
52-week high
$6.28
52-week low
$1.03
Change from 52-week high
-43.3%
Change from 52-week low
+245.6%
Annualized volatility
133.7%
Annualized volatility (3M)
67.2%
Beta
0.6
RSI (14D)
28.6
Price vs SMA 50
-31.6%
Price vs SMA 200
-10.1%
Avg volume (3M)
250,908
Relative volume
0.5
Average dollar volume
$1.30M
Company
3 metricsSector
Healthcare
Industry
Biotechnology
Shares outstanding
37.74M
Valuation
12 metricsP / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
1.8
reciprocal yield 56.8%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-27.2%
Historical valuation
8 metricsP / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
—
Last earnings
2026-05-19
Profitability
9 metricsGross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$38.81M
Net income (TTM)
−$36.28M
Trailing 12 months
Diluted EPS (TTM)
$-1.07
FCF margin
—
Effective tax rate
—
Growth
11 metricsRevenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+48.4%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
-47.8%
Return on assets
-44.4%
Debt / equity
0.0
Current ratio
14.3
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
14.3
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$44.32M
Latest balance sheet
Cash & equivalents
$44.32M
Total assets
$81.68M
Total debt
$0
Cash flow & spend
7 metricsOperating cash flow (TTM)
−$30.68M
Capital expenditures (TTM)
—
R&D (TTM)
$26.64M
SG&A (TTM)
—
Stock compensation (TTM)
$4.63M
R&D / revenue
—
Stock compensation / revenue
—
Ownership (13F)
9 metrics13F filers
66
13F filer change QoQ
+14
Institutional ownership
65.1%
Conviction holders (share of 13F filers)
0.0%
Crowding (high-turnover and private-fund holders)
52.4%
Private-fund adviser ownership
49.6%
Active holders' share change QoQ
+1.2%
Holder tenure
3.9
Price vs estimated holder cost
+70.8%
Ownership (registered funds)
1 metricsIndex-fund ownership
6.7%
Short interest
3 metricsShort interest
6.6%
Latest settlement · 9.5 days to cover
Days to cover
9.5d
Short-squeeze score
70 / 100
Insider activity
2 metricsNet insider buying (90D)
−$306,603
Insider-sentiment score
70 / 100
Risk flags
1 metricsGoing concern
—